0.00
100.00%
-1.725
Eiger BioPharmaceuticals Inc 주식(EIGR)의 최신 뉴스
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Sentynl acquires Eiger's Zokinvy for progeria treatment - Pharmaceutical Technology
Pharmaceutical Technology
StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR) - Defense World
Defense World
Sentynl Therapeutics, a Zydus company acquires Zokinvy for Progeria from Eiger Biopharma - Medical Dialogues
Medical Dialogues
Biotech Eiger Says Ch. 11 Should Stay In Texas - Law360
Law360
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford ... - PR Newswire
PR Newswire
Eiger Gets Deal With Merck Over $46M Rare-Disease Drug Sale - Law360
Law360
Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market Latest Trends &Innovations | Eiger ... - Amoré
Amoré
Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11 - Law360
Law360
Eiger Lacks Ties to Texas to File for Bankruptcy There, DOJ Says - Bloomberg Law
Bloomberg Law
Requiem for Eiger Biopharmaceuticals - WSJ - The Wall Street Journal
The Wall Street Journal
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Biotech Eiger Can Take Sentynl's Improved Drug Bid In Ch. 11 - Law360
Law360
Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year - BioSpace
BioSpace
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
GlobeNewswire Inc.
Dow Falls Over 200 Points; ISM Manufacturing PMI Rises In March
Benzinga
Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives - Benzinga
Benzinga
EIGR Stock Quote Price and Forecast - CNN
CNN
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and ... - PR Newswire
PR Newswire
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase - Yahoo Finance
Yahoo Finance
Dow Surges 150 Points; US Jobless Claims Decline Sharply
Benzinga
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - PR Newswire
PR Newswire
Eiger scraps phase III but delta force deploying in hepatitis - BioWorld Online
BioWorld Online
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - PR Newswire
PR Newswire
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Appoints New Management Team - Contract Pharma
Contract Pharma
Elizabeth Warren, AOC Ask SVB Depositors to Detail Ties to Bank - Bloomberg
Bloomberg
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - PR Newswire
PR Newswire
Silicon Valley Bank's stranded deposits spread the pain from Tech Valley to Napa Valley - The Economic Times
The Economic Times
Eiger BioPharmaceuticals (EIGR): The Results Are In - The CEO And The CFO Are Out - Seeking Alpha
Seeking Alpha
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in ... - PR Newswire
PR Newswire
Investigation announced for Long-Term Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) - openPR
openPR
EIGR stock plunges after late-stage data for chronic hepatitis candidate (NASDAQ:EIGR) - Seeking Alpha
Seeking Alpha
Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA ... - PR Newswire
PR Newswire
Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and ... - PR Newswire
PR Newswire
Eiger BioPharmaceuticals presents liver study data - Labiotech.eu
Labiotech.eu
Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post ... - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus ... - PR Newswire
PR Newswire
AnGes and Eiger collaborate to distribute Zokinvy in Japan - Pharmaceutical Technology
Pharmaceutical Technology
Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and ... - PR Newswire
PR Newswire
Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and ... - PR Newswire
PR Newswire
Eiger Appoints New Executive Leadership - Contract Pharma
Contract Pharma
Eiger Biopharmaceuticals Offers Opportunity (NASDAQ:EIGR) - Seeking Alpha
Seeking Alpha
Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a ... - PR Newswire
PR Newswire
Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in ... - PR Newswire
PR Newswire
자본화:
|
볼륨(24시간):